Your browser doesn't support javascript.
loading
Lower facial remodeling with botulinum toxin type A for the treatment of masseter hypertrophy
Klein, Fernanda Homem de Mello de Souza; Brenner, Fabiane Mulinari; Sato, Maurício Shigeru; Robert, Fernanda Manfron Batista Rosas; Helmer, Karin Adriane.
  • Klein, Fernanda Homem de Mello de Souza; Private practice particular - Criciúma (SC), Brazil. Criciúma. BR
  • Brenner, Fabiane Mulinari; Private practice particular - Criciúma (SC), Brazil. Criciúma. BR
  • Sato, Maurício Shigeru; Private practice particular - Criciúma (SC), Brazil. Criciúma. BR
  • Robert, Fernanda Manfron Batista Rosas; Private practice particular - Criciúma (SC), Brazil. Criciúma. BR
  • Helmer, Karin Adriane; Private practice particular - Criciúma (SC), Brazil. Criciúma. BR
An. bras. dermatol ; 89(6): 878-884, Nov-Dec/2014. tab, graf
Artigo em Inglês | LILACS | ID: lil-727648
ABSTRACT

BACKGROUND:

Masseter hypertrophy has been treated with botulinum toxin injections because of esthetic complaints especially in Asians.

OBJECTIVES:

The goal of the present study was to evaluate the efficacy of abobotulin toxin use in masseter hipertrophy treatment in Brazilians.

METHODS:

Ten Brazilian female patients with masseter hypertrophy were subjected to injections of 90U of abobotulinum toxin A applied on each side respecting the safety zone stabilished in literature and were followed up for 24 weeks.

RESULTS:

When analyzing the coefficients between measures of middle and lower third of the face obtained from standardized photographs, an increase was observed, with statistical significance at 2 weeks (p=0.005) and 12 weeks (p=0.001). The progression of lower third reduction was 3.94%, 5.26%, 11.99%, and 5.47% (2, 4, 12, and 24 weeks respectively). All patients showed improvement in bruxism after treatment. Observed adverse effects were masticatory fatigue, smile limitation, and smile asymmetry.

CONCLUSION:

The use of abobotulinum toxin A for masseter hypertrophy is effective in Brazilians and reached its maximum effect of facial thinning at 12 weeks. Smile limitation had a higher incidence compared to that reported in the literature and may result from risorius muscle blockage caused by toxin dissemination. Despite its side effects, 80% of the patients would like to repeat the treatment. .
Assuntos


Texto completo: DisponíveL Índice: LILACS (Américas) Assunto principal: Toxinas Botulínicas Tipo A / Hipertrofia / Músculo Masseter / Fármacos Neuromusculares Tipo de estudo: Estudos de avaliação Limite: Adulto / Feminino / Humanos País/Região como assunto: América do Sul / Brasil Idioma: Inglês Revista: An. bras. dermatol Assunto da revista: Dermatologia Ano de publicação: 2014 Tipo de documento: Artigo País de afiliação: Brasil Instituição/País de afiliação: Private practice particular - Criciúma (SC), Brazil/BR

Similares

MEDLINE

...
LILACS

LIS


Texto completo: DisponíveL Índice: LILACS (Américas) Assunto principal: Toxinas Botulínicas Tipo A / Hipertrofia / Músculo Masseter / Fármacos Neuromusculares Tipo de estudo: Estudos de avaliação Limite: Adulto / Feminino / Humanos País/Região como assunto: América do Sul / Brasil Idioma: Inglês Revista: An. bras. dermatol Assunto da revista: Dermatologia Ano de publicação: 2014 Tipo de documento: Artigo País de afiliação: Brasil Instituição/País de afiliação: Private practice particular - Criciúma (SC), Brazil/BR